Search Results - "Dees, Claire"

Clinical subtype, treatment response, and survival in De Novo and recurrent metastatic breast cancer by File, Danielle M., Pascual, Tomas, Deal, Allison M., Wheless, Amy, Perou, Charles M., Claire Dees, E., Carey, Lisa A.

“…Purpose This study evaluated whether patients with de novo metastatic breast cancer (MBC) have superior outcomes compared to those with recurrent MBC in a…”
Get full text

The Triple Negative Paradox: Primary Tumor Chemosensitivity of Breast Cancer Subtypes by CAREY, Lisa A, DEES, E. Claire, SAWYER, Lynda, GATTI, Lisa, MOORE, Dominic T, COLLICHIO, Frances, OLLILA, David W, SARTOR, Carolyn I, GRAHAM, Mark L, PEROU, Charles M

“…Purpose: Gene expression analysis identifies several breast cancer subtypes. We examined the relationship of neoadjuvant chemotherapy response to outcome among…”
Get full text

Gedatolisib in combination with palbociclib and endocrine therapy in women with hormone receptor-positive, HER2-negative advanced breast cancer: results from the dose expansion groups of an open-label, phase 1b study by Layman, Rachel M, Han, Hyo S, Rugo, Hope S, Stringer-Reasor, Erica M, Specht, Jennifer M, Dees, E Claire, Kabos, Peter, Suzuki, Samuel, Mutka, Sarah C, Sullivan, Brian F, Gorbatchevsky, Igor, Wesolowski, Robert

“…The PI3K–mTOR pathway is frequently dysregulated in breast cancer. Combining an inhibitor targeting all class I PI3K isoforms and mTOR complex 1 (mTORC1)–mTOR…”
Get full text

Safety and activity of alisertib, an investigational aurora kinase A inhibitor, in patients with breast cancer, small-cell lung cancer, non-small-cell lung cancer, head and neck squamous-cell carcinoma, and gastro-oesophageal adenocarcinoma: a five-arm phase 2 study by Melichar, Bohuslav, Prof, Adenis, Antoine, Prof, Lockhart, A Craig, MD, Bennouna, Jaafar, Prof, Dees, E Claire, Prof, Kayaleh, Omar, MD, Obermannova, Radka, MD, DeMichele, Angela, MD, Zatloukal, Petr, Prof, Zhang, Bin, DSc, Ullmann, Claudio Dansky, MD, Schusterbauer, Claudia, MD

“…Summary Background Alisertib is an investigational, oral, selective inhibitor of aurora kinase A. We aimed to investigate the safety and activity of…”
Get full text

Nanoparticle-Delivered Chemotherapy: Old Drugs in New Packages by Lee, Michael S, Dees, E Claire, Wang, Andrew Z

“…Cytotoxic chemotherapies have a narrow therapeutic window, with high peaks and troughs of plasma concentration. Novel nanoparticle formulations of cytotoxic…”
Get more information

A first in man phase I trial of the oral immunomodulator, indoximod, combined with docetaxel in patients with metastatic solid tumors by Soliman, Hatem H, Jackson, Erica, Neuger, Tony, Dees, E Claire, Harvey, R Donald, Han, Hyo, Ismail-Khan, Roohi, Minton, Susan, Vahanian, Nicholas N, Link, Charles, Sullivan, Daniel M, Antonia, Scott

“…Indoleamine 2,3-dioxygenase (IDO) is an enzyme that tumors use to create a state of immunosuppression. Indoximod is an IDO pathway inhibitor. Preclinical…”
Get full text

Phase I Study of Aurora A Kinase Inhibitor MLN8237 in Advanced Solid Tumors: Safety, Pharmacokinetics, Pharmacodynamics, and Bioavailability of Two Oral Formulations by DEES, E. Claire, COHEN, Roger B, MEHREN, Margaret Von, STINCHCOMBE, Thomas E, HUA LIU, VENKATAKRISHNAN, Karthik, MANFREDI, Mark, FINGERT, Howard, BURRIS, Howard A, INFANTE, Jeffrey R

“…This phase I study evaluated the safety, pharmacokinetics, pharmacodynamics, and efficacy of the investigational oral drug MLN8237 (alisertib), a…”
Get full text

Modernizing Clinical Trial Eligibility Criteria: Recommendations of the ASCO-Friends of Cancer Research Washout Period and Concomitant Medication Work Group by Harvey, R Donald, Mileham, Kathryn F, Bhatnagar, Vishal, Brewer, Jamie R, Rahman, Atiqur, Moravek, Cassadie, Kennedy, Andrew S, Ness, Elizabeth A, Dees, E Claire, Ivy, S Percy, Ebbinghaus, Scot W, Schenkel, Caroline, Uldrick, Thomas S

“…Washout periods and concomitant medication exclusions are common in cancer clinical trial protocols. These exclusion criteria are often applied inconsistently…”
Get full text

First‐in‐human, phase I/IIa study of CRLX301, a nanoparticle drug conjugate containing docetaxel, in patients with advanced or metastatic solid malignancies by Piha-Paul, Sarina A., Thein, Kyaw Z., De Souza, Paul, Kefford, Richard, Gangadhar, Tara, Smith, Christopher, Schuster, Shelly, Zamboni, William C., Dees, Claire E., Markman, Ben

“…Summary Background This was a phase I/IIa study to investigate the tolerability, efficacy and pharmacokinetics (PK)/ pharmacodynamics (PD) of CRLX301,…”
Get full text

Genotype-Guided Tamoxifen Dosing Increases Active Metabolite Exposure in Women With Reduced CYP2D6 Metabolism: A Multicenter Study by IRVIN, William J, WALKO, Christine M, RAAB, Rachel E, CORSO, Steven W, PEPPERCORN, Jeffrey M, ANDERSON, Steven M, FRIEDMAN, Kenneth J, OGBURN, Evan T, DESTA, Zeruesenay, FLOCKHART, David A, MCLEOD, Howard L, EVANS, James P, WECK, Karen E, CAREY, Lisa A, IBRAHIM, Joseph G, CHIU, WingK, DEES, E. Claire, MOORE, Susan G, OLAJIDE, Oludamilola A, GRAHAM, Mark L, CANALE, Sean T

“…We examined the feasibility of using CYP2D6 genotyping to determine optimal tamoxifen dose and investigated whether the key active tamoxifen metabolite,…”
Get full text

CYP2C83 predicts benefit/risk profile in breast cancer patients receiving neoadjuvant paclitaxel by Hertz, Daniel L., Motsinger-Reif, Alison A., Drobish, Amy, Winham, Stacey J., McLeod, Howard L., Carey, Lisa A., Dees, E. Claire

“…Paclitaxel is one of the most frequently used chemotherapeutic agents for the treatment of breast cancer patients. Using a candidate gene approach, we…”
Get full text

Risk Perceptions and Psychosocial Outcomes of Women With Ductal Carcinoma In Situ: Longitudinal Results From a Cohort Study by Partridge, Ann, Adloff, Kristie, Blood, Emily, Dees, E. Claire, Kaelin, Carolyn, Golshan, Mehra, Ligibel, Jennifer, de Moor, Janet S., Weeks, Jane, Emmons, Karen, Winer, Eric

“…Background Ductal carcinoma in situ (DCIS) has a generally favorable overall prognosis, with a systemic recurrence rate of approximately 1%, a local recurrence…”
Get full text

The Proteasome as a Target for Cancer Therapy by VOORHEES, Peter M, DEES, E. Claire, O'NEIL, Bert, ORLOWSKI, Robert Z

“…The proteasome is a multicatalytic proteinase complex responsible for the degradation of most intracellular proteins, including proteins crucial to cell cycle…”
Get full text

Phase I and Pharmacokinetic Study of Sorafenib in Patients With Hepatic or Renal Dysfunction: CALGB 60301 by MILLER, Antonius A, MURRY, Daryl J, LEWIS, Lionel D, FAKIH, Marwan G, EDELMAN, Martin J, MILLARD, Fred, FRANK, Richard C, HOHL, Raymond J, RATAIN, Mark J, OWZAR, Kouros, HOLLIS, Donna R, KENNEDY, Erin B, ABOU-ALFA, Ghassan, DESAI, Apurva, HWANG, Jimmy, VILLALONA-CALERO, Miguel A, DEES, E. Claire

“…We sought to characterize the pharmacokinetics (PK) and determine a tolerable dose of oral sorafenib in patients with hepatic or renal dysfunction. Patients…”
Get full text

Phase I Safety, Pharmacokinetics, and Clinical Activity Study of Lapatinib (GW572016), a Reversible Dual Inhibitor of Epidermal Growth Factor Receptor Tyrosine Kinases, in Heavily Pretreated Patients With Metastatic Carcinomas by Burris, 3rd, Howard A, Hurwitz, Herbert I, Dees, E Claire, Dowlati, Afshin, Blackwell, Kimberly L, O'Neil, Bert, Marcom, Paul K, Ellis, Matthew J, Overmoyer, Beth, Jones, Suzanne F, Harris, Jennifer L, Smith, Deborah A, Koch, Kevin M, Stead, Andrew, Mangum, Steve, Spector, Neil L

“…This study (EGF10004) assessed the safety/tolerability, pharmacokinetics, and clinical activity of daily oral dosing with lapatinib (GW572016) in patients with…”
Get full text

A biomarker of aging, p16, predicts peripheral neuropathy in women receiving adjuvant taxanes for breast cancer by Mitin, Natalia, Nyrop, Kirsten A., Strum, Susan L., Knecht, Anne, Carey, Lisa A., Reeder-Hayes, Katherine E., Claire Dees, E., Jolly, Trevor A., Kimmick, Gretchen G., Karuturi, Meghan S., Reinbolt, Raquel E., Speca, JoEllen C., O’Hare, Erin A., Muss, Hyman B.

“…Identifying patients at higher risk of chemotherapy-induced peripheral neuropathy (CIPN) is a major unmet need given its high incidence, persistence, and…”
Get full text

The interaction of post-traumatic growth and post-traumatic stress symptoms in predicting depressive symptoms and quality of life by Morrill, E. Forrest, Brewer, Noel T., O'Neill, Suzanne C., Lillie, Sarah E., Dees, E. Claire, Carey, Lisa A., Rimer, Barbara K.

“…Objective: We sought to explore whether post‐traumatic growth (PTG) (positive change or benefit finding resulting from trauma) moderates relationships between…”
Get full text

Changing Natural History of HER2–Positive Breast Cancer Metastatic to the Brain in the Era of New Targeted Therapies by Mounsey, Louisa A., Deal, Allison M., Keith, Kevin C., Benbow, Julia M., Shachar, Shlomit S., Zagar, Timothy, Dees, E. Claire, Carey, Lisa A., Ewend, Matthew G., Anders, Carey K.

“…Patients with breast cancer brain metastases historically have a poor prognosis. In this single-institution cohort study of patients with human epidermal…”
Get full text

Abemaciclib in Combination With Endocrine Therapy for Patients With Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer: A Phase 1b Study by Tolaney, Sara M, Beeram, Muralidhar, Beck, J Thaddeus, Conlin, Alison, Dees, E Claire, Puhalla, Shannon L, Rexer, Brent N, Burris, Howard A, Jhaveri, Komal, Helsten, Teresa, Becerra, Carlos, Kalinsky, Kevin, Moore, Kathleen N, Manuel, Allison M, Lithio, Andrew, Price, Gregory L, Chapman, Sonya C, Litchfield, Lacey M, Goetz, Matthew P

“…Cyclin-dependent kinases (CDK) 4 and 6 regulate G1 to S cell cycle progression and are often altered in cancers. Abemaciclib is a selective inhibitor of CDK4…”
Get full text

Study of the Biologic Effects of Lapatinib, a Reversible Inhibitor of ErbB1 and ErbB2 Tyrosine Kinases, on Tumor Growth and Survival Pathways in Patients With Advanced Malignancies by Spector, Neil L, Xia, Wenle, Burris, 3rd, Howard, Hurwitz, Herbert, Dees, E Claire, Dowlati, Afshin, O'Neil, Bert, Overmoyer, Beth, Marcom, Paul K, Blackwell, Kimberly L, Smith, Deborah A, Koch, Kevin M, Stead, Andrew, Mangum, Steven, Ellis, Matthew J, Liu, Leihua, Man, Albert K, Bremer, Troy M, Harris, Jennifer, Bacus, Sarah

“…This was a pilot study to assess the biologic effects of lapatinib on various tumor growth/survival pathways in patients with advanced ErbB1 and/or…”
Get full text